PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(3)
dated December 8, 2000 Registration No. 333-36318
to Prospectus dated August 2, 2000
$200,000,000
INCYTE GENOMICS, INC.
5.5% CONVERTIBLE SUBORDINATED NOTES DUE 2007
and
SHARES OF COMMON STOCK
ISSUABLE UPON CONVERSION OF THE NOTES
This prospectus supplement relates to the resale by the holders of 5.5%
convertible subordinated notes due 2007 of Incyte Genomics, Inc. and the shares
of common stock issuable upon conversion of the notes.
This prospectus supplement should be read in conjunction with the
prospectus dated August 2, 2000, which is to be delivered with this prospectus
supplement.
The information in the table appearing under the heading "Selling
Securityholders" in the prospectus is supplemented and superseded in part by the
information appearing in the table below:
<TABLE>
<CAPTION>
Principal Common Stock Common Stock
Amount of Notes Issuable Upon Owned After
Beneficially Conversion Completion
Owned and of the Common Stock of the
Name Offered(1) Notes(1)(2) Offered(1)(2) Offering(1)
---- --------------- -------------- --------------- --------------
<S> <C> <C> <C> <C>
PGEP V LLC .................................... $500,000 7,416 7,416 __
----------------------
<FN>
(1) Amounts indicated may be in excess of the total amount registered due to sales or transactions exempt from
the registration requirements of the Securities Act of 1933 since the date on which selling
securityholders provided information to us regarding their notes.
None of the selling securityholders listed above nor any of their affiliates, officers, directors or principal
equity holders has held any position or office or has had any material relationship with us within the past
three years.
(2) Amounts indicated reflect a 2-1 stock split effected in the form of a stock dividend on August 31, 2000.
--------------------
Investing in the notes and our common stock involves a high degree of risk.
You should carefully read and consider the "Risk Factors" beginning on page 3 of
the prospectus.
</FN>
</TABLE>
--------------------
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the
accuracy or adequacy of this prospectus supplement or the prospectus. Any
representation to the contrary is a criminal offense.
Prospectus Supplement dated December 8, 2000
